VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ARMP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ARMPArmata Pharmaceuticals, Inc.
$7.20$264M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksARMPBalance Sheet

Armata Pharmaceuticals, Inc. (ARMP) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial position is severely strained, with total debt reaching $373.7M and a current ratio of 0.64, indicating significant insolvency risk.

ARMP Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96Dec'95Dec'94Dec'93
Total Current Assets5.95M10.67M11.31M19.15M27.05M14.99M10.85M6.66M8.41M5.38M6.36M10.02M7.02M20.53M1.65M5.67M19.3M8.23M15.19M35.15M21.63M14.23M29.49M42.19M9.3M12.4M5.3M19.5M14.6M11.7M6.9M
Cash & Short-Term Investments4.75M8.69M9.29M13.52M14.85M10.29M9.65M6.03M8.16M5.13M5.71M9.37M6.58M20.36M862K5.22M16.44M6.21M14.12M34.1M21.06M12.61M25.19M38.63M7.2M1.9M1M3.5M2.2M2.3M1.2M
Cash Only4.75M8.69M9.29M13.52M14.85M10.29M9.65M6.03M8.16M5.13M5.71M9.37M6.58M20.36M862K5.22M16.44M6.21M14.12M34.1M21.06M12.61M25.19M38.63M4.1M1.9M1M3.5M2.2M2.3M1.2M
Short-Term Investments0000000000000000000000003.1M000000
Accounts Receivable47K472K744K3.36M1.94M2.99M561K00025K125K100K8K641K317K2.61M1.5M380K404K166K1.17M3.37M3.26M1.8M000000
Days Sales Outstanding106.335.1352.49271.03128.29243.85248.8---35.196.0589.248.98352.3613.2792.2455.4320.1815.284.3122.0965.11104.4796.62------
Inventory0000000000-619K00000000000000000000
Days Inventory Outstanding-------------------------------
Other Current Assets1.15M1.51M1.27M2.27M10.26M00622K0253K602K521K339K171K0132K000653K409K00291.44K300K10.5M4.3M16M12.4M9.4M5.7M
Total Non-Current Assets63.85M66.21M75.13M79.21M80.83M54.77M28.67M18.8M3.48M5.75M11.84M21.48M21.6M17.41M20.42M1.49M9.18M9.23M33.61M34.81M36.04M38.48M41.55M45.79M4.4M3.8M4.5M5.6M5.4M5.3M5.2M
Property, Plant & Equipment45.17M46.1M54.93M57.28M46.65M38.07M12.84M4.21M503K816K1.07M1.13M1.22M145K136K1.28M1.05M1.1M1.75M2.5M3.42M5.52M8.31M6.21M4M3.3M3.9M5M5M5M4.9M
Fixed Asset Turnover0.06x0.11x0.09x0.08x0.12x0.12x0.06x--0.14x0.24x0.42x0.34x2.24x4.88x6.78x9.82x8.97x3.93x3.87x4.11x3.50x2.27x1.84x1.70x2.18x0.23x0.46x0.02x0.08x0.02x
Goodwill3.49M3.49M3.49M3.49M3.49M3.49M3.49M3.49M0007.56M7.56M4.33M7.41M07.93M7.93M31.65M31.65M00000000000
Intangible Assets10.26M10.26M10.26M10.26M10.26M10.26M10.26M10.26M2.98M4.94M10.77M12.78M12.81M12.94M12.88M0000031.65M31.65M31.75M37.82M000000300K
Long-Term Investments9.51M5.39M5.48M05.96M01.2M700K800K0000000000000000000000
Other Non-Current Assets813K973K975K8.19M2.43M2.96M-2.13M135K136K000000200K200K206K217K668K968K1.31M1.49M1.76M400K500K600K600K400K300K0
Total Assets69.8M76.88M86.44M98.36M107.88M69.77M39.52M25.45M11.89M11.14M18.2M31.49M28.62M37.95M22.07M7.15M28.47M17.47M48.8M69.97M57.67M52.71M71.04M87.97M13.7M16.2M9.8M25.1M20M17M12.1M
Asset Turnover0.04x0.06x0.06x0.05x0.05x0.06x0.02x--0.01x0.01x0.02x0.01x0.01x0.03x1.22x0.36x0.56x0.14x0.14x0.24x0.37x0.27x0.13x0.50x0.44x0.09x0.09x0.01x0.02x0.01x
Asset Growth %-65.34%-11.05%-12.12%-8.82%54.62%76.56%55.26%114.11%6.72%-38.79%-42.23%10.05%-24.59%71.93%208.69%-74.89%63.02%-64.21%-30.25%21.32%9.41%-25.8%-19.25%542.15%-15.43%65.31%-60.96%25.5%17.65%40.5%-
Total Current Liabilities9.23M8.95M48.25M16.46M24.87M4.81M6.71M4.88M2.57M1.97M3.58M2.38M1.87M2.15M6.05M3.99M4.66M5.19M4.63M4M6.71M11.28M11.63M12.69M4.6M3.3M2.7M3.5M1.8M1.6M900K
Accounts Payable660K921K766K1.58M6.03M1.14M956K547K729K578K1.06M1.04M1.17M2.15M1.94M02.16M1.9M1.77M1.29M1.27M2.01M3.45M4M2.3M1.7M1.4M1.9M600K700K600K
Days Payables Outstanding424.21219.578.12595.1962.920.7524.16147.78196.95564.091.04K--9.56K--44.5447.9135.527.2126.9824.6833.5-822.54-524.69-387.81-319.38-365-156.43-196.54-547.5
Short-Term Debt4.59M4.56M38.95M017.01M0722K1.31M00803K0003.65M0336K1.13M155K1.27M1.29M1.3M1.31M838K1.2M1.2M1M1.3M900K600K200K
Deferred Revenue (Current)0000000000933K245K244K001.23M79K251K278K01.18M6.04M4.63M00000000
Other Current Liabilities3.98M3.46M529K1.29M001.94M1.7M1.35M340K826K420K000001.05M0407K1.4M01.12M7.85M1.1M400K300K300K300K300K100K
Current Ratio0.64x1.19x0.23x1.16x1.09x3.11x1.62x1.36x3.27x2.74x1.78x4.20x3.76x9.56x0.27x1.42x4.14x1.59x3.28x8.80x3.22x1.26x2.54x3.33x2.02x3.76x1.96x5.57x8.11x7.31x7.67x
Quick Ratio0.64x1.19x0.23x1.16x1.09x3.11x1.62x1.36x3.27x2.74x1.95x4.20x3.76x9.56x0.27x1.42x4.14x1.59x3.28x8.80x3.22x1.26x2.54x3.33x2.02x3.76x1.96x5.57x8.11x7.31x7.67x
Cash Conversion Cycle-317.9------------------------------
Total Non-Current Liabilities372.16M286.53M86.21M113.97M46.92M39.56M13.95M5.98M841K1.44M4.89M16.39M23.31M50.02M3.08M6.94M7.58M6.91M13.6M16.21M16.73M34.78M22.01M11.86M2.1M900K1.5M2.1M2.4M2.2M1M
Long-Term Debt342.9M256.92M55.44M82.31M0000000000000570K8.18M10.18M11.23M20.49M16.4M2.45M2.1M900K1.5M2.1M2.4M2.3M1M
Capital Lease Obligations106.68M26.53M27.69M28.58M31.8M36.48M10.88M1.55M00000000000000000000000
Deferred Tax Liabilities12.31M3.08M3.08M3.08M15.12M3.08M3.08M3.08M819K1.15M2.45M3M3.08M03.08M0000000-4.97M00000000
Other Non-Current Liabilities00000001.35M22K292K2.44M13.39M20.23M50.02M06.94M7.58M6.34M5.42M6.03M5.51M14.29M12.65M9.41M00000-100K0
Total Liabilities381.39M295.48M134.46M130.43M71.8M44.37M20.66M10.86M3.41M3.41M8.47M18.78M25.18M52.17M9.13M10.92M12.23M12.1M18.23M20.2M23.44M46.07M33.64M24.54M6.7M4.2M4.2M5.6M4.2M3.8M1.9M
Total Debt373.67M288.02M126.52M120.37M48.81M37.99M13.15M2.86M00803K0003.65M0336K1.7M8.33M11.45M12.52M21.79M17.71M3.28M3.3M2.1M2.5M3.4M3.3M2.9M1.2M
Net Debt368.92M279.33M117.22M106.85M33.96M27.7M3.5M-3.17M-8.16M-5.13M-4.91M-9.37M-6.58M-20.36M2.79M-5.22M-16.11M-4.51M-5.79M-22.64M-8.54M9.19M-7.47M-35.35M-800K200K1.5M-100K1.1M600K0
Debt / Equity-1.20x---1.35x1.50x0.70x0.20x--0.08x---0.28x-0.02x0.32x0.27x0.23x0.37x3.28x0.47x0.05x0.47x0.18x0.45x0.17x0.21x0.22x0.12x
Debt / EBITDA-10.49x------------------------------
Net Debt / EBITDA-10.36x------------------------------
Interest Coverage-8.79x-1.88x-3.95x-25.29x-1274.00x-360.80x-34.32x-19.92x------21.56x-11.57x--14406.00x-84.48x-34.45x-30.01x-7.11x-12.98x-63.28x-172.43x--30.33x--30.25x-34.67x-41.50x-
Total Equity-311.59M-218.6M-48.02M-32.06M36.08M25.4M18.86M14.59M8.47M7.73M9.72M12.71M3.44M-14.22M12.94M-3.77M16.24M5.37M30.57M49.76M34.23M6.65M37.4M63.43M7M12M5.6M19.5M15.8M13.2M10.2M
Equity Growth %-972.86%-355.23%-49.76%-188.87%42.06%34.68%29.22%72.21%9.61%-20.49%-23.53%269.92%124.17%-209.87%443.13%-123.23%202.59%-82.44%-38.57%45.38%415.03%-82.23%-41.04%806.17%-41.67%114.29%-71.28%23.42%19.7%29.41%-
Book Value per Share-8.53-6.03-1.33-0.891.051.051.151.8625.5016.941383.66328.9474.35-983.681886.18-1323.516890.113839.0624996.7343843.1741667.7310161.9259581.488401.541087.972252.681386.485943.317502.3711000.00391.16
Total Shareholders' Equity-311.59M-218.6M-48.02M-32.06M36.08M25.4M18.86M14.59M8.47M7.73M9.72M12.71M3.44M-14.22M12.94M-3.77M16.24M5.37M30.57M49.76M33.48M5.9M37.4M63.43M7M12M5.6M19.5M15.8M13.2M10.2M
Common Stock366K364K362K361K361K271K187K99K323K95K165K59K1.99M1.82M669K202K198K109K857K856K662K506K441K200.97M98.1M000000
Retained Earnings-616.88M-501.53M-327.74M-308.82M-239.77M-202.86M-179.7M-157.52M-406.32M-394.21M-381.36M-362.52M-362.01M-387.24M-320.53M-320.87M-300.15M-284.03M-250.04M-230.84M-216.58M-201.75M-177.98M-150.81M-103.5M-76.5M-67.8M-53.6M-27.6M-17.8M-9.3M
Treasury Stock000000000-401.84M000000000000000000000
Accumulated OCI000000000-11.14M-18.2M-1.49M-12.32M-65K000-39K-21K0-750K0-12.02M-13.28M-12.3M000000
Minority Interest00000000000000000000750K750K000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Equity and Rising Liabilities

As reported in recent financial filings, Armata’s balance sheet trajectory shows significant deterioration, with total equity plummeting to -$311.6M in 2026Q1 from -$32.1M in 2023Q4, driven by persistent operating losses that have effectively wiped out the company's book value and necessitated heavy reliance on debt financing.

The consistent expansion of the deficit in retained earnings suggests that the company is consuming capital at a rate that far outstrips its ability to generate value through its clinical pipeline. This trend indicates a business model that is currently unable to achieve self-sustainability, forcing a reliance on external capital that continues to dilute existing shareholders.

Debt Burden Outpacing Asset Base

Based on the company's reported figures, total debt has surged to $373.7M as of 2026Q1, creating a precarious leverage profile where liabilities significantly exceed total assets of $69.8M, signaling a high degree of financial distress and limited flexibility for future capital structure optimization.

The accumulation of debt appears to be a necessity-driven survival mechanism rather than a strategic choice to fund growth, given the lack of corresponding revenue expansion. Investors should monitor the terms of these obligations, as the high debt-to-asset imbalance may restrict the company's ability to secure additional non-dilutive funding.

Tightening Cash Runway and Liquidity

According to recent balance sheet data, Armata’s liquidity position remains critically strained, with a current ratio of 0.64 in 2026Q1 and cash reserves of only $4.8M, which appears insufficient to cover the company's ongoing quarterly operating burn without immediate access to additional capital.

The volatility in the current ratio, which has fluctuated significantly over the past ten quarters, highlights the company's dependence on the timing of milestone payments or external financing. This lack of a stable liquidity buffer leaves the firm highly vulnerable to operational delays or unfavorable shifts in capital market conditions.

Hidden Risks in Capital Structure

As indicated by the financial statements, the most non-obvious risk is the company's extreme negative equity position, which suggests that the firm is technically insolvent on a book-value basis and relies entirely on the continued support of major shareholders to remain a going concern.

This structural distortion makes traditional valuation metrics like price-to-book irrelevant and shifts the focus entirely to the company's ability to secure further financing. The reliance on a single benefactor for liquidity creates a concentration risk that could lead to unfavorable terms for minority shareholders in future capital raises.

ARMP — Frequently Asked Questions

Quick answers to the most common questions about buying ARMP stock.

What are the total assets of Armata Pharmaceuticals, Inc. (ARMP)?

As of 2025, Armata Pharmaceuticals, Inc. (ARMP) had total assets of $76.9M including $10.7M in current assets.

How much debt does Armata Pharmaceuticals, Inc. (ARMP) have?

Armata Pharmaceuticals, Inc. (ARMP) carries total debt of $288.0M, offset by $8.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Armata Pharmaceuticals, Inc.?

Armata Pharmaceuticals, Inc. (ARMP) has total shareholders' equity (book value) of $-218.6M ($-6.03 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Armata Pharmaceuticals, Inc.'s current ratio and liquidity?

Armata Pharmaceuticals, Inc. (ARMP) reported a current ratio of 1.19x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.